Prediabetes in general practitioner’s clinical practice

Česká verzia

Authors: M. Jenšovský ¹; J. Malinovská ¹; J. Urbanová ²; Z. Nosková ¹; M. Lustigová ^3,4; S. Pálová ¹; J. Brož ¹
Authors place of work: Interní klinika 2. LF UK a FN Motol, Praha, Přednosta: prof. MUDr. Milan Kvapil, CSc., MBA ¹; Interní klinika 3. LF UK a FNKV, Praha, Přednosta: prof. MUDr. Ivan Rychlík, CSc., FASN, FERA ²; Přírodovědecká fakulta UK, Praha, Děkan: prof. RNDr. Jiří Zima, CSc. ³; Státní zdravotní ústav, Praha, Ředitel: MUDr. Pavel Březovský, MBA ⁴
Published in the journal: Prakt. Lék. 2021; 101(1): 8-11
Category: Of different specialties

Summary

Prediabetes is an important topic for the general practitioners due to its increasing prevalence and a new option to bill the code for care for a prediabetic patient. The prevalence of prediabetes in the Czech Republic based on HbA_1c measurement was 26.6% in men and 25,3% in women in a population aged 25–64. We present a review that focuses on prediabetes epidemiology, diagnostic options and risk factors with regard to the Czech Republic and prediabetes complications and treatment options.

Keywords:

prediabetes – diabetic complications – cardiovascular complications – general practitioner

Zdroje

1. Seznam zdravotních výkonů s bodovými hodnotami [online]. Dostupné z: https://www.vzp.cz/poskytovatele/informace-pro-praxi/vykazovani-a-uhrady/seznam-zdravotnich-vykonu-s-bodovymi-hodnotami [cit. 6. 5. 2020].

2. Perušičová J, Pelikánová T, Škrha J, a kol. Doporučený postup péče o nemocné s prediabetem. DMEV 2012; 15(1): 20–22.

3. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43(Suppl 1): S14–S31.

4. NICE. Type 2 diabetes: prevention in people at high risk. Public health guideline [PH38] [online]. Dostupné z: www.nice.org.uk/guidance/ph38 [cit. 2021-01-22].

5. International Diabetes Federation. IDF Diabetes Atlas. 9^thEd. Brussels, Belgium: 2019 [online]. Dostupné z: https://www.diabetesatlas.org [cit. 2021-01-22].

6. Hostalek U. Global epidemiology of prediabetes – present and future perspectives. Clin Diabetes Endocrinol 2019; 5(1): 2055–8260.

7. Brož J, Malinovská J, Nunes MA, et al. Prevalence of diabetes and prediabetes and its risk factors in adults aged 25–64 in the Czech Republic: A cross-sectional study. Diabetes Res Clin Pract 2020; 170: 108470.

8. Gonzalez-Rivas JP, Mechanick JI, Infante-Garcia MM, et al. Prevalence of Dysglycemia-Based Chronic Disease (DBCD) in European Population: a new paradigm to address diabetes burden. The Kardiovize Study. Endocrine Practice [online]. Dostupné z: https://www.endocrinepractice.org/article/S1530-891X(20)48360-0/pdf [cit. 2021-01-22].

9. Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016; 355: i5953.

10. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733): 2215–2222.

11. Açar B, Ozeke O, Karakurt M, et al. Association of prediabetes with higher coronary atherosclerotic burden among patients with first diagnosed acute coronary syndrome. Angiology 2019; 70(2): 174–180.

12. Brannick B, Wynn A, Dagogo‐Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macro‐ vascular complications. Exp Biol Med (Maywood) 2016; 241(12): 1323–1331.

13. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent‐onset diabetes in the Diabetes Prevention Program. Diabet Med 2007; 24(2): 137–144.

14. Lamparter J, Raum P, Pfeiffer N, et al. Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. J Diabetes Complications 2014; 28: 482–487.

15. Bahar A, Makhlough A, Yousefi A, et al. Correlation between prediabetes conditions and microalbuminuria. Nephrourol Mon 2013; 5(2): 741–744.

16. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011; 7(11): 682–690.

17. Mack CI, Ferrario PG, Weinert CH, et al. Exploring the diversity of sugar compounds in healthy, prediabetic, and diabetic volunteers. Mol Nutr Food Res 2020; 64(9): e1901190.

18. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379(9833): 2279–2290.

19. Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol 2019; 7(6): 452–461.

20. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403.

21. Cosentino F, Grant PJ, Aboyans V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), 2020. Eur Heart J 2019; 41(2): 255–323.

22. Daniele G, Abdul-Ghani M, Defronzo RA. What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 2014; 15(14): 2003–2018.

23. Karen I, Svačina Š, Šmahelová A, a kol. Prediabetes. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Novelizace 2016 [online]. Dostupné z: https://www.svl.cz/files/files/Doporucene-postupy-od-2013/Prediabetes-2016.pdf [cit. 2021-01-22].